Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

10 results
Display

A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout

Lee J, Kim J, Ghang B, Jeong W

Background/Aims: The occurrence of gout attacks at the start of uric acid lowering treatment worsens compliance. We aimed to determine the appropriate dose of febuxostat to reduce the occurrence of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease

Waheed Y, Yang F, Sun D

Previous research has investigated whether hyperuricemia serves as an independent risk factor for cardiovascular and renal diseases. Hyperuricemia is defined as an abnormally high level of uric acid (UA; i.e.,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4–5 chronic kidney disease not yet on dialysis

Kim SH, Lee SY, Kim JM, Son CN

Background/Aims: The safety and efficacy of febuxostat in patients with stage 4–5 chronic kidney disease (CKD) are still unclear owing to a lack of studies in these patients. Therefore, we...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
What is the Best Choice for Urate-lowering Therapy for Korean?

Cheon YH, Song JS

Gout is one of the most common forms of acute inflammatory arthritis caused by long-standing hyperuricemia. Various clinical and epidemiological studies have demonstrated that uric acid, which is strongly associated...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of Efficacy and Safety of Febuxostat in Gout Patients with Chronic Kidney Disease Stage 3 and Stage 4/5

Ahn E, Lee S, Lee HN, Lee SG, So MW

OBJECTIVE: To compare efficacy and safety of febuxostat in gouty patients with chronic kidney disease (CKD) stage 3 and stage 4/5. METHODS: Age and sex matched patients with CKD stage 3...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis

Kim S, Kim HJ, Ahn HS, Oh SW, Han KH, Um TH, Cho CR, Han SY

BACKGROUND: Hyperuricemia is reported to be related to rapid progression of renal function in patients with chronic kidney disease (CKD). Allopurinol, a uric acid lowering agent, protects renal progression. However,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparative Efficacy and Safety of Febuxostat and Allopurinol in the Treatment of Hyperuricemia: A Bayesian Network Meta-analysis

Song GG, Lee YH

OBJECTIVE: The aim of this study was to assess the relative urate-lowering efficacy and safety of febuxostat and allopurinol in hyperuricemic patients with or without gout. METHODS: Randomized controlled trials (RCTs)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Febuxostat for the Treatment of Chronic Tophaceous Gout in a Patient on Continuous Ambulatory Peritoneal Dialysis

Yun JH, Kim HY, Kim DH, Oh JS, Kim SM, Sin YH, Kim JK

Hyperuricemic patients with gouty arthritis or tophi, a serum uric acid concentration of 8.0 mg/dL or higher, and complications should be treated with urate-lowering drugs. Conventionally, allopurinol is used to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Four-Week Effects of Allopurinol and Febuxostat Treatments on Blood Pressure and Serum Creatinine Level in Gouty Men

Kim HA, Seo YI, Song YW

The aim of this study was to observe the effects of uric acid lowering therapy (UALT), febuxostat and allopurinol, on blood pressure (BP) and serum creatinine level. Post-hoc data were...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Urate-lowering Efficacy and Safety of Febuxostat in Korean Patients with Gout

Park SH, Song YW, Park W, Koh EM, Yoo B, Lee SK, Yoo DH, Lee YJ, Kim HA, Choi HJ, Kim HY, Jung HG

OBJECTIVE: To compare the urate-lowering efficacy and the safety of febuxostat, allopurinol and placebo in Korean patients with gout for 4 weeks. METHODS: Subjects (n=182) with gout were randomized to febuxostat...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr